LON:AZN - AstraZeneca Stock Price, News, & Analysis

Get Started

GBX 6,089 +76.00 (+1.26 %)

(As of 05/26/2019 08:02 AM ET)

Previous CloseGBX 6,089

Today's RangeGBX 5,981 - GBX 6,103

52-Week RangeGBX 5,110 - GBX 6,540

Volume1.87 million shs

Average Volume2.31 million shs

Market Capitalization£79.87 billion

P/E Ratio32.05

Dividend Yield3.76%

BetaN/A

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON

Industry Drug Manufacturers - Major

Sub-IndustryN/A

SectorMedical

Current SymbolLON:AZN

Previous Symbol

CUSIPN/A

CIKN/A

Webhttp://www.astrazeneca.com/

Phone+44-20-73045000

Debt

Debt-to-Equity Ratio179.66

Current Ratio0.75

Quick Ratio0.57

Price-To-Earnings

Trailing P/E Ratio32.05

Forward P/E Ratio15.94

P/E GrowthN/A

Sales & Book Value

Annual Sales£22.40 billion

Price / Sales3.57

Cash FlowGBX 404.36 per share

Price / Cash Flow15.06

Book ValueGBX 799.20 per share

Price / Book7.62

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees64,400

Outstanding Shares1,311,760,000

Market Cap£79.87 billion

Next Earnings Date7/25/2019 (Estimated)

OptionableOptionable

AstraZeneca (LON:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a dividend on Thursday, February 14th. Shareholders of record on Thursday, February 28th will be paid a dividend of GBX 146.80 per share on Wednesday, March 27th. This represents a dividend yield of 2.57%. The ex-dividend date of this dividend is Thursday, February 28th. This is a boost from AstraZeneca's previous dividend of $68.40. The official announcement can be accessed at this link. View AstraZeneca's Dividend History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for AstraZeneca.

What price target have analysts set for AZN?

20 brokerages have issued twelve-month price targets for AstraZeneca's stock. Their forecasts range from GBX 5,000 to GBX 8,500. On average, they expect AstraZeneca's share price to reach GBX 6,480.56 in the next twelve months. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for AstraZeneca.

What is the consensus analysts' recommendation for AstraZeneca?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 sell ratings, 6 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

Headlines about AZN stock have trended negative this week, according to InfoTrie. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AstraZeneca earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the company's share price in the near term.

Who are some of AstraZeneca's key competitors?

Some companies that are related to AstraZeneca include GlaxoSmithKline (GSK), Bayer (BAYN), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Mayne Pharma Group (MYX), Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Opthea (OPT), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Futura Medical (FUM) and Vita Life Sciences (VLS).

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), Hain Celestial Group (HAIN), Vodafone Group (VOD), National Retail Properties (NNN), BP (BP), NVIDIA (NVDA), Philip Morris International (PM), Marks and Spencer Group (MKS), British American Tobacco Plc Ads (BATS) and Ford Motor (F).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:

Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)
Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
Thomas Kudsk Larsen, Head of Investor Relations
Mr. Jefrey Pott, Gen. Counsel

How do I buy shares of AstraZeneca?

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately GBX 6,089.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of £79.87 billion and generates £22.40 billion in revenue each year. AstraZeneca employs 64,400 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is http://www.astrazeneca.com/.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.

MarketBeat Community Rating for AstraZeneca (LON AZN)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		1,385 (Vote Outperform)
Underperform Votes:		1,574 (Vote Underperform)
Total Votes:		2,959

MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 5/26/2019 by MarketBeat.com Staff

Featured Article: Diluted Earnings Per Share